(Q33834630)

English

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Taimur Sher

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sikander Ailawadhi

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Kena C Miller

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Debbie Manfredi

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Margaret Wood

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Wei Tan

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gregory Wilding

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Myron S Czuczman

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Francisco J Hernandez-Ilizaliturri

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Fredrick Hong

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Raman Sood

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Saif Soniwala

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

William Lawrence

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Saad Jamshed

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Aisha Masood

15

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel Iancu

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Kelvin Lee

17

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Asher Chanan-Khan

18

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

9 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

154

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

104-110

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Primary dexamethasone treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

4 July 2018

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08703.X

21 January 2018

Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08703.X

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08703.X

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08703.X

21 January 2018

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08703.X

21 January 2018

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078729

29 October 2018

The development of a model for the homing of multiple myeloma cells to human bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/21554260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2011.08703.X

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33834630&oldid=1533738443"